Clinical development
- Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
16 Sep, 2024 - 5 Late-Stage mRNA Vaccines to Watch
16 Sep, 2024 - A vaccine could become a ‘vital’ weapon against pancreatic cancer
16 Sep, 2024 - Breast cancer vaccine to enter clinical trial phase
16 Sep, 2024 - Experimental mRNA Cancer Vaccine Shows Promise in Patients With Advanced Cancers
16 Sep, 2024 - Researchers say lung cancer vaccine could come soon
15 Sep, 2024 - Cancer jab shows promise in early trial results
15 Sep, 2024 - Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
14 Sep, 2024 - ICMR to advance 1st in-human trials for Zika, flu, blood cancer therapies
14 Sep, 2024 - Indian Immunologicals Sign Pact For Clinical Development Of Zika Vaccine
14 Sep, 2024 - ESMO: IO Biotech’s vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
14 Sep, 2024 - Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase I trial
13 Sep, 2024 - Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
13 Sep, 2024 - CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
13 Sep, 2024 - GSK presents positive mRNA seasonal influenza vaccine data
13 Sep, 2024 - ESMO: Moderna’s mRNA solid tumour vaccine shows early promise
13 Sep, 2024 - 130 lung cancer patients from six countries given experimental mRNA vaccine as study commences
13 Sep, 2024 - ‘Encouraging’ Early Data for mRNA Vaccine in Glioblastoma
13 Sep, 2024 - Q&A: Vaccine fails to prevent C. difficile infection but reduces symptom duration
13 Sep, 2024 - New vaccine shows promise in treating patients with advanced cancers
12 Sep, 2024 - Promising Lassa fever vaccine is headed to phase I clinical trial
12 Sep, 2024 - GSK’s HSV Vaccine Study Fails to Meet Primary Efficacy Goal
12 Sep, 2024 - Birmingham opens first pancreatic cancer mRNA vaccine trial in Europe
12 Sep, 2024 - Vaxxas launches Phase I trial for H7N9 influenza vaccine
12 Sep, 2024 - Monkey Pox vaccine: Bavarian Nordic’s smallpox vaccine found 58% effective after one dose
12 Sep, 2024 - GSK’s Phase I/II herpes simplex vaccine trial misses primary endpoint
12 Sep, 2024 - Merck’s Gardasil 9 vaccine meets primary endpoint in Phase 3 trial
12 Sep, 2024 - Another Herpes Vaccine Candidate Flops
12 Sep, 2024 - Doherty Clinical Trials to conduct trial of Australian-developed needle-free vaccine for avian influenza
12 Sep, 2024 - Moderna Focuses on Influenza – COVID Combination Vaccine Candidate
12 Sep, 2024 - Trial to assess personalized vaccine for aggressive brain tumors
12 Sep, 2024 - GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
11 Sep, 2024 - Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
11 Sep, 2024 - Versatope Launches Clinical Development Team for VT-105, a Pan-influenza A Vaccine Candidate
11 Sep, 2024 - Merck’s HPV vaccine meets key goals in Japanese study (NYSE:MRK)
11 Sep, 2024 - Chinese vaccine for mpox gets clearance for clinical trials
11 Sep, 2024 - Sanofi’s high-dose vaccine targets flu vulnerabilities in older adults
11 Sep, 2024 - Vaccination Protects Japanese Men from HPV Cancers
11 Sep, 2024 - China Approves Sinopharm’s Mpox Vaccine For Clinical Trials
10 Sep, 2024 - 2 new vaccines may be first step toward curing brain cancer
10 Sep, 2024 - 69% Overall Response Rate in Cancer Vaccine Candidate Phase 2 Study
10 Sep, 2024 - Chikungunya Vaccine Confirmed Effective and Safe
10 Sep, 2024 - Global Phase 3 Study Launches for Second-Line Non-Small Cell Lung Cancer Vaccine
10 Sep, 2024 - Vaccine trial volunteer works to empower her community, end HIV
09 Sep, 2024 - Evaxion’s cancer vaccine EVX-01 reports 69% response rate
09 Sep, 2024 - CureVac to present CVGBM glioblastoma cancer vaccine data at ESMO
09 Sep, 2024
0 Comments